Regeneron Pharmaceuticals, Inc.
A fully integrated biotech that discovers and manufactures medicines for serious diseases, best known for EYLEA (for retinal conditions), Dupixent (for allergic and inflammatory diseases), and cancer drug Libtayo. Founded in 1988 by neurologist Leonard Schleifer and scientist George Yancopoulos, the company got its name by blending "regenerating neurons" with "gene" — reflecting its early dream of rebuilding damaged brain cells. It now grows drug-making cells in huge bioreactors at sites in New York and Ireland, and taps its own genetics center to find new drug targets.
Granted 175.4K
Granted 201.3K
Granted 38.7K
Granted 29.2K
Granted 3.7K
Granted 9.4K
Granted 9.3K
Granted 155 · Sold 400
Granted 2.5K
Granted 155
Granted 155
Granted 3.1K · Sold 2.5K
Granted 9.4K · Sold 6.5K
Granted 1.8K · Sold 1.6K
Granted 2.4K · Sold 2.3K
Granted 155
Granted 155
Granted 155
Granted 155
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Yancopoulos GeorgeBd. Co-Chair, President & CSO, Director · 4 transactions | — | 1.13M | 175.4K | — | — |
| Schleifer Leonard SBd. Co-Chair, President & CEO, Director · 4 transactions | — | 716.6K | 201.3K | — | — |
| Murphy Andrew JEVP Research · 6 transactions | -2.2% | 52.2K | 38.7K | — | — |
| Larosa Joseph JEVP General Counsel and Secret · 6 transactions | — | 45.6K | 29.2K | — | — |
| Van Plew Daniel PEVP & General Mgr, Industrial · 3 transactions | — | 35.2K | 3.7K | — | — |
| Sing George LDirector · 3 transactions | +10.6% | 33.2K | 9.4K | — | — |
| Fenimore Christopher R.EVP Finance CFO · 4 transactions | +19.2% | 23.5K | 9.3K | — | — |
| Ryan Arthur FDirector · 48 transactions | -0.9% | 17.6K | 155 | — | 400 |
| McCourt MarionEVP Commercial · 3 transactions | +1% | 14.5K | 2.5K | — | — |
| Brown Michael SDirector · 1 transaction | +1.2% | 12.9K | 155 | — | — |
| Goldstein Joseph LDirector · 1 transaction | +2.4% | 6.7K | 155 | — | — |
| Pitofsky JasonSVP Controller · 15 transactions | — | 5.8K | 3.1K | — | 2.5K |
| Poon Christine ADirector · 9 transactions | +121.9% | 5.2K | 9.4K | — | 6.5K |
| Zoghbi Huda YDirector · 13 transactions | +109.4% | 3.2K | 1.8K | — | 1.6K |
| Bassler Bonnie LDirector · 5 transactions | +106.9% | 3.2K | 2.4K | — | 2.3K |
| Coles N AnthonyDirector · 1 transaction | +9.9% | 1.7K | 155 | — | — |
| Thompson Craig B.Director · 1 transaction | +25% | 775 | 155 | — | — |
| Guarini KathrynDirector · 1 transaction | +34.6% | 603 | 155 | — | — |
| Schenkein David PDirector · 1 transaction | +34.6% | 603 | 155 | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last year: -13.3K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.